MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)
Effective date
Not stated in the notice
Identified
Jun 19, 2026
Summary
This is a routine annual policy reissue with NO SUBSTANTIVE CHANGES to Independence Blue Cross Medicare Advantage coverage of Triamcinolone Acetonide ER Injectable (Zilretta) for knee osteoarthritis. The policy maintains existing medical necessity criteria, coverage limitations, and billing codes. No new billing requirements or workflow changes are needed.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.